AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03626090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BM MSC
Description: A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
Study NCT02920229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga- PSMA
Description: 100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
Study NCT00865943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HBr eq. 10 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT00865943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CELEXATM 10 mg tablets, single dose
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
Study NCT01768546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Prevention Program
Description: Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
Study NCT01768546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive tracking and problem solving web portal
Study NCT00586170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBI Bone Healing System
Description: 10 hours of treatment per day for up to 24 weeks
Study NCT00586170 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: 10 hours of treatment per day for up to 24 weeks
Study NCT00586170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Open Reduction and Internal Fixation of the nonunion site
Study NCT00586170 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Open Reduction and Internal Fixation of the nonunion site
Study NCT03755167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPL344
Description: IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
Study NCT01986101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT01986101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Description: SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
Study NCT01986101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496
Description: SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
Study NCT03114917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive AppRoaches to coMbatting Suicidality (CARMS)
Description: The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
Study NCT02628132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given weekly for 6 cycles
Study NCT02628132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be given q2 wks concurrently with paclitaxel.
Study NCT00576732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution qd or bid for 6 weeks
Study NCT00576732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone high dose
Description: Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
Study NCT00576732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone low dose
Description: Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
Study NCT01339286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
Study NCT02607371 — intervention group
Intervention type: OTHER
Intervention: VKAs
Description: VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02607371 — intervention group
Intervention type: OTHER
Intervention: NOACs including Rivaroxaban (Xarelto, BAY59-7939)
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02607371 — intervention group
Intervention type: OTHER
Intervention: Edoxaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02607371 — intervention group
Intervention type: OTHER
Intervention: Apixaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT02607371 — intervention group
Intervention type: OTHER
Intervention: Dabigatran-etexilate
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study NCT00800280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Single 300 mg dose of PD 0332334 immediate release capsules administered orally
Study NCT00800280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
Study NCT00800280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cimetidine
Description: 600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
Study NCT03771196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioactive Restorative Material
Description: enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
Study NCT03771196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin-modified glass ionomer
Description: Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
Study NCT01996358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
Study NCT01996358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,3
Description: General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
Study NCT01996358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,6
Description: General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
Study NCT04706533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers of inflammation
Description: Biomarkers were measured on blood samples collected within 48 hours of admission
Study NCT03670056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination immunotherapy with Ipilimumab and Nivolumab
Description: Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
Study NCT00612534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab
Description: 5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study NCT00612534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NanoTab
Description: Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study NCT00612534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab
Description: 10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study NCT00612534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study NCT02805036 — intervention group
Intervention type: DEVICE
Intervention: echocardiography
Description: • Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
Study NCT02805036 — intervention group
Intervention type: DEVICE
Intervention: Arterial oximetry
Description: measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
Study NCT02536885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal group
Description: If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
Study NCT02536885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive group
Description: If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
Study NCT04656860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus+
Description: Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match albiglutide
Description: albiglutide matching placebo weekly subcutaneous injection
Study NCT00839527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection
Study NCT01667367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: Single oral dose
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride
Study NCT04656860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice Plus+
Description: Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: glimepiride
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match pioglitazone
Description: pioglitazone matching placebo
Study NCT00839527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to match pioglitazone
Description: pioglitazone matching placebo
Study NCT01667367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral dose
Study NCT03115138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
Description: The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
Study NCT01782417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: patient and provider intervention
Description: Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
Study NCT02179970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
Study NCT00584402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perflutren lipid microspheres
Description: perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
Study NCT01336621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine IR
Description: Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
Study NCT03967002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group with corticotomy surgery
Description: The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~* the second premolars and first premolars,~* the first lower premolars and canines,~* the canines and lateral incisors,~* the lateral incisors and central incisors, and,~* the two lower central incisors.
Study NCT03051685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose 1
Study NCT03051685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose 2
Study NCT03051685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose 3
Study NCT03051685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Study NCT01712880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open debridement with modular exchange
Study NCT01712880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one stage exchange
Study NCT04469738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours
Study NCT04469738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is functioning
Study NCT02579096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol capsule, 100-800 mg by mouth once daily
Description: Patients will be up-titrated up to the dose required to reach target uric acid levels.
Study NCT02579096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablet 40-120 mg by mouth once daily
Description: Patients will be up-titrated to the dose required to reach target uric acid levels.
Study NCT02579096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, vehicle control (febuxostat-shaped)
Description: Placebo tablets resembling febuxostat will be given with allopurinol.
Study NCT02579096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, vehicle control (allopurinol-shaped)
Description: Placebo capsules resembling allopurinol will be given with febuxostat.
Study NCT03650582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Intranasal glucagon
Study NCT03650582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo
Study NCT00980603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
Study NCT00980603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin
Description: docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
Study NCT00980603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, S-1
Description: docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
Study NCT01576588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
Study NCT01576588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
Study NCT03002649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
Study NCT03847558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males
Description: assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
Study NCT03561506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
Study NCT03561506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.